Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative…
Orelabrutinib is a Phase 2 oral small molecule Bruton’s tyrosine kinase inhibitor with high selectivity and the ability to cross the blood-brain barrierInnoCare to receive a $125 million upfront payment and is eligible to receive potential…